Targeted therapies for MASH show progress, with pegozafermin leading in efficacy for fibrosis regression and disease resolution. The lack of head-to-head trials complicates treatment prioritization, ...

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended granting conditional marketing authorization to semaglutide (Kayshild, Novo Nordisk) for ...

A soldier wounded in Korea in 1951 had better survival odds than soldiers wounded in World War II despite heavier casualties and harsher conditions. The difference was time. Mobile Army Surgical ...

Altimmune has shared an update on the metabolic dysfunction-associated steatohepatitis (MASH) study that sank its stock in June. The 48-week readout linked the top dose of the GLP-1/glucagon dual ...

Semaglutide, the popular weight loss and diabetes drug, now has the green light to treat moderate to severe metabolic dysfunction-associated steatohepatitis (MASH). If you have the condition and are ...

Please provide your email address to receive an email when new articles are posted on . AIM-MASH AI Assist is the first AI drug development tool to be qualified by the FDA. The tool is designed to ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...

In my last note on Altimmune, Inc. (ALT) shared in late August, I made the bull case for its stock. I discussed the Gaithersburg, Maryland based biotech's lead and only drug candidate, pemvidutide, ...